Back to Search
Start Over
Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
- Source :
-
Inflammatory bowel diseases [Inflamm Bowel Dis] 2016 Aug; Vol. 22 (8), pp. 1779-92. - Publication Year :
- 2016
-
Abstract
- Background: Distinction between 2 forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD), can be challenging. Aberrant mucosal immunity suggests that CD is a T helper type 1 cell (Th1)-driven disease, whereas UC as Th2-driven response. However, whether this paradigm truly distinguishes CD from UC is controversial. We aimed to clarify the discriminating potential of lamina propria Th subsets in patients with IBD.<br />Methods: Biopsies from 79 patients with IBD and 20 healthy controls were collected for Th subsets analysis (Th1:interferon γ [IFN-γ], T-bet; Th2:interleukin 13 [IL-13], Gata3; Th17:IL-17, RORγt; Treg:FoxP3). The receiver-operating characteristic curves were constructed to assess the discriminating ability by calculating the area under the receiver-operating characteristic curve. The equation with the highest area under the receiver-operating characteristic curve was applied to newly diagnosed patients to evaluate discriminating ability.<br />Results: Patients with CD showed increased IFN-γ or T-bet cells and decreased IL-13 or Gata3 cells compared with UC. A discriminant equation composed of 4 markers (IFN-γ, T-bet, IL-13, and Gata3) yielded the highest area under the receiver-operating characteristic curve. In 36 established CD or UC, the sensitivity, specificity, positive and negative predictive probabilities were 92.6%, 55.6%, 86.2%, and 71.4% and in 14 newly diagnosed patients were 100.0%, 42.9%, 63.6%, and 100.0%. Furthermore, Gata3 cells were increased in tumor necrosis factor inhibitor therapy nonresponders compared with responders in CD. IFN-γ cells were directly and inversely proportional to disease activity in patients with CD and UC, respectively.<br />Conclusions: The Th1/Th2 paradigm can distinguish CD from UC and may be further associated with response to tumor necrosis factor inhibitor in CD and disease activity in patients with IBD.
- Subjects :
- Adalimumab therapeutic use
Adolescent
Adult
Aged
Anti-Inflammatory Agents therapeutic use
Biopsy
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes drug effects
CD4-Positive T-Lymphocytes metabolism
Colitis, Ulcerative drug therapy
Colitis, Ulcerative pathology
Crohn Disease drug therapy
Crohn Disease pathology
Female
Flow Cytometry
Forkhead Transcription Factors metabolism
GATA3 Transcription Factor metabolism
Humans
Immunity, Mucosal drug effects
Infliximab therapeutic use
Interferon-gamma metabolism
Interleukin-13 metabolism
Interleukin-17 metabolism
Interleukin-2 Receptor alpha Subunit metabolism
Intestinal Mucosa pathology
Male
Middle Aged
Predictive Value of Tests
Severity of Illness Index
T-Box Domain Proteins metabolism
T-Lymphocyte Subsets drug effects
T-Lymphocyte Subsets metabolism
T-Lymphocytes, Regulatory metabolism
Th1 Cells metabolism
Th17 Cells metabolism
Th2 Cells metabolism
Young Adult
CD4-Positive T-Lymphocytes pathology
Colitis, Ulcerative diagnosis
Colitis, Ulcerative immunology
Crohn Disease diagnosis
Crohn Disease immunology
Intestinal Mucosa immunology
T-Lymphocyte Subsets pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1536-4844
- Volume :
- 22
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Inflammatory bowel diseases
- Publication Type :
- Academic Journal
- Accession number :
- 27243594
- Full Text :
- https://doi.org/10.1097/MIB.0000000000000811